Oxford BioMedica PLC (OXBDF)

[georgejjl]

CAR-T 5T4 cell therapy: OXB-302 for targeting solid cancer
tumours
OXB-302 combines three technology platforms – LentiVector, 5T4 tumour antigen and CAR-T – for
the development of a CAR-T 5T4 targeted therapy for the treatment of solid cancers. 5T4 is a
heavily glycosylated cell surface protein that is expressed on a diverse range of cancer cells but
demonstrates low levels of expression on non-cancerous tissues, making 5T4 an attractive target
for therapeutic intervention. Expression of 5T4 ranges from 100% on metastatic prostate, lung,
breast, renal and colorectal cancers to between 75-100% of the primary tumours. CAR-Ts are
modified T-cells that express a chimeric antigen receptor (CAR) that is specific for a target protein.
To create CAR-Ts a patient’s T-cells are harvested then transduced with the lentiviral vector
encoding for a particular receptor, in this case 5T4. These cells are then expanded and infused
back into the patient where they search for the cells expressing 5T4, effectively hunting out the
cancerous cells to destroy them. This therapeutic class has demonstrated some exceptional
efficacy, counter balanced by a high incidence of severe side effects. OXB-302 is currently in
preclinical trials and the preclinical work is on track to be completed by the end of the year. We
therefore currently do not include any sales expectations for the product given its early stage in
development and the intense competition in the CAR-T space. We highlight this programme as one
to watch as it progresses into clinical trials given the magnitude of patients with solid tumours; a
successful CAR-T therapy could ensure blockbuster sales potential.

http://www.edisoninvestmentresearch.com/research/report/oxford-biomedica29/full

Good luck and GOD bless,

George